Fulton Breakefield Broenniman LLC Vertex Pharmaceuticals Inc Transaction History

Fulton Breakefield Broenniman LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Jan 14, 2021	SELL	$207.01 - $276.09 $554,579 - $739,645	-2,679 Closed	0 $0
Q3 2020 Oct 20, 2020	SELL	$255.65 - $303.1 $10,481 - $12,427	-41 Reduced 1.51%	2,679 $729,000
Q2 2020 Jul 10, 2020	BUY	$225.48 - $295.8 $5,411 - $7,099	24 Added 0.89%	2,720 $790,000
Q1 2020 Apr 10, 2020	BUY	$199.77 - $247.81 $8,989 - $11,151	45 Added 1.7%	2,696 $642,000
Q4 2019 Jan 14, 2020	BUY	$166.71 - $223.91 $52,513 - $70,531	315 Added 13.48%	2,651 $580,000
Q3 2019 Oct 17, 2019	BUY	$166.23 - $187.09 $388,313 - $437,042	2,336 New	2,336 $396,000

1,716

225M

1.19M

1.56M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $129B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Fulton Breakefield Broenniman LLC, based on Form 13F filings with the SEC.

Stay updated on Fulton Breakefield Broenniman LLC with notifications on news.